NovaBay Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $2,400 | $2,631 | $3,727 | $3,255 |
Gross Profit | 1,592 | 1,794 | 1,815 | 1,838 |
EBITDA | -1,042 | -1,559 | -748 | -1,116 |
EBIT | -1,053 | -1,571 | -798 | -1,167 |
Net Income | -1,585 | -3,214 | -4,107 | -1,757 |
Net Change In Cash | 2,400 | 2,631 | 3,727 | 3,255 |
Free Cash Flow | -676 | -1,593 | -203 | -365 |
Cash | 751 | 1,823 | 3,130 | 3,472 |
Basic Shares | 1,155 | 24,672 | 11,230 | 4,692 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $14,726 | $14,404 | $8,421 | $9,934 |
Gross Profit | 7,895 | 7,781 | 5,645 | 5,964 |
EBITDA | -4,800 | -4,545 | -13,358 | -1,162 |
EBIT | -5,003 | -5,028 | -13,477 | -1,213 |
Net Income | -9,640 | -16,265 | -6,559 | -11,039 |
Net Change In Cash | 14,726 | 14,404 | 8,421 | 9,934 |
Cost of Revenue | 5,015 | |||
Free Cash Flow | -4,331 | -6,766 | -9,244 | -4,747 |
Cash | 3,130 | 5,362 | 7,504 | 11,952 |
Basic Shares | 4,215 | 1,610 | 1,247 | 1,002 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | -$1.37 |
2024-03-31 | -$0.15 |
2023-12-31 | -$1.33 |
2023-09-30 | -$0.37 |
